NuView Life Sciences

NuView Life Sciences is pioneering a targeted copper theranostics (TCT) platform centered on its proprietary NV-VPAC1 ligand, which binds to VPAC1 receptors overexpressed on a wide range of cancers. The company is developing a pipeline of in vitro diagnostics, PET imaging agents, and radiotherapeutics for cancers including prostate, bladder, breast, brain, and pancreatic. Its approach aims to offer precise tumor localization and targeted treatment delivery, potentially improving patient outcomes and expanding access to radiopharmaceuticals. NuView is a private, clinical-stage company with a robust intellectual property portfolio and multiple programs advancing toward clinical development.

Proprietary small molecule (NV-VPAC1) targeting VPAC1 receptors (a GPCR subtype) overexpressed on cancer cells. Modular platform enables paired diagnostic (Cu-64) and therapeutic (Cu-67) radiopharmaceuticals (Targeted Copper Theranostics/TCT), as well as in vitro diagnostic assays (liquid biopsy).

NuView operates in the competitive radiopharmaceutical theranostics space, competing with large players like Novartis (Pluvicto) and Bayer, as well as numerous biotech companies. Its differentiation lies in its specific VPAC1 target and its paired copper isotope approach, which it claims offers logistical advantages. However, it must prove clinical superiority or equivalence to established and emerging therapies targeting other pathways (e.g., PSMA, FAP).